









Markets
/
Stocks
/
nasdaq-bcda
/

BioCardia Inc

BCDA

1.250USD

+0.010+0.81%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

13.26MMarket Cap

LossP/E TTM



BioCardia Inc

1.250

+0.010+0.81%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of BioCardia Inc

Currency: USD Updated: 2026-02-06

Key Insights

BioCardia Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 169 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 25.00.In the medium term, the stock price is expected to remain stable.Despite a weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

BioCardia Inc's Score

Industry at a Glance

Industry Ranking

169 / 392

Overall Ranking

320 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

BioCardia Inc Highlights

StrengthsRisks

BioCardia, Inc. is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases. It is advancing two cell therapy platforms derived from bone marrow, such as CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia. Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being advanced as a cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome. Its CardiAMP autologous and CardiALLO allogeneic cell therapies are the Company’s biotherapeutic platforms with three clinical stage product candidates in development. These therapies are enabled by its Helix biotherapeutic delivery and Morph vascular navigation product platforms.

Growing

The company is in a growing phase, with the latest annual income totaling USD 58.00K.

Fairly Valued

The company’s latest PE is -0.88, at a medium 3-year percentile range.

Held by The Vanguard

Star Investor The Vanguard holds 135.56K shares of this stock.

Analyst Rating

Based on 2 analysts

Buy

Current Rating

25.000

Target Price

+1916.13%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of BioCardia Inc is 6.59, ranking 237 out of 392 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

6.59

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

6.88

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.69

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.36

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.03

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

BioCardia Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of BioCardia Inc is 8.68, ranking 27 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.88, which is -53.91% below the recent high of -0.41 and -386.79% above the recent low of -4.30.

Score

Industry at a Glance

Previous score

8.68

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 169/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of BioCardia Inc is 8.00, ranking 164 out of 392 in the Biotechnology & Medical Research industry. The average price target is 15.50, with a high of 25.00 and a low of 6.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 2 analysts

Buy

Current Rating

25.000

Target Price

+1916.13%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

BioCardia Inc

BCDA

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of BioCardia Inc is 2.85, ranking 373 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 1.42 and the support level at 1.08, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

2.84

Change

0.01

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(3)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-0.022

Sell

RSI(14)

47.056

Neutral

STOCH(KDJ)(9,3,3)

42.573

Buy

ATR(14)

0.086

Low Volatility

CCI(14)

-36.625

Neutral

Williams %R

52.941

Neutral

TRIX(12,20)

-0.367

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

1.190

Buy

MA10

1.241

Buy

MA20

1.304

Sell

MA50

1.326

Sell

MA100

1.345

Sell

MA200

1.763

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of BioCardia Inc is 3.00, ranking 197 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 3.11%, representing a quarter-over-quarter decrease of 17.06%. The largest institutional shareholder is The Vanguard, holding a total of 135.56K shares, representing 1.28% of shares outstanding, with 363.97% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Lincoln Alternative Strategies LLC

800.00K

Satterfield (Thomas A Jr)

736.00K

+119.05%

Blank (Andrew Scott)

636.06K

+340.07%

Altman (Peter)

267.97K

+23.62%

The Vanguard Group, Inc.

Star Investors

96.50K

+648.98%

CM Management, LLC

130.00K

Allen (Jim L)

109.66K

Stertzer (Simon H)

79.40K

-33.10%

Mcclung (David)

76.89K

+60.35%

Stertzer Family Trust

59.20K

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of BioCardia Inc is 3.02, ranking 177 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 0.60. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.